Items 1 ~ 8 of 2032, Page 1 of 254
New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System
Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies
New Approvals Allow Chronic Pain Sufferers to Try Abbott''s Non-Opioid Pain Therapy Before Getting Device Implant
Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were uns...
Abbott and The Chertoff Group Explore Current State of Cybersecurity in the Connected Hospital
New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity...
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for Thes...
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC
ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ --?Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mill...
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV G-ZEBOV-GP) to U.S. Food and Drug Administration
V920 is the Company's Investigational Vaccine for Ebola Zaire
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease
FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Approval Would Expand Use of AstraZeneca and Merck’s LYNPARZA to These Patients in the First-Line Setting Following Platinum-Based Chemotherapy / Firs...